[ad_1]
An article was published in The Lancet that reviews a study of more than 200 patients with COVID-19 in central Wuhan, China. Doctors in the study found no positive change in the remdesivir-treated group compared to the adult control group.
The findings came shortly after US pharmaceutical giant Gilead, the maker of remdesivir, said a large-scale trial of the drug in coronavirus-infected patients had shown positive results.
“Unfortunately, our trial shows that remdesivir, while safe and well tolerated, did not provide significant benefits compared to placebo,” said Bin Cao, lead author of the study at the China-Japan Friendship Hospital and the University of Capital Medicine.
“It is not the result we expected,” he added.
The Uhane study included 237 patients with COVID-19, half of whom received remdesivir. The other side became the control group; Its members were treated with conventional antibiotics.
Mortality was the same in both groups, about 14 percent.
On the other hand, patients requiring ventilator-treated patients treated with remdesivir spent much less time connecting to the devices, averaging seven days, rather than 15 as controls.
“No significant differences were found between the groups in terms of [reikalingos] duration of oxygen respiratory support, length of hospital stay, or time before discharge or death, “the researchers said.
The authors of the article said their study had some drawbacks, including the fact that it stopped prematurely after a sharp drop in patients after the coronavirus outbreak in Uhane subsided.
However, experts have called for the continuation of randomized clinical trials with this product.
[ad_2]
